Immunodeficiency: Back from the brink of obscurity
A mutation in a transcription factor makes people susceptible to Trophyrema whippelii, the bacterium that causes a rare condition called Whipple's disease.
- McGill University Health Centre, Canada
- The Research Institute of the McGill University Health Centre, Canada
Throughout history, human health has been perpetually challenged by pestilence. In the late 19th century, 'germ theory' established the role of specific microbes in infectious diseases. However, it later became apparent that only a few of the individuals who are exposed to a microbe go on to develop a disease, and even fewer die. Why does this happen? Now, in eLife, Jean-Laurent Casanova and colleagues – including Antoine Guérin as first author – report one answer to this question for an obscure infection known as Whipple's disease (Guérin et al., 2018).
In 1907, George Whipple described a fatal disease that was marked by pain spreading through the joints, chronic diarrhea, excessive fat in the feces, and weight loss (Whipple, 1907). Under the microscope, he saw fatty material accumulate in the intestine and surrounding lymph nodes (Figure 1); he also noted abnormal 'foamy' cells with an associated rod-shaped microbe. Subsequent reports highlighted that this disease spread systemically through the body, affecting various organs.
Figure 1
Biopsy of the small intestine showing features classic for Whipple’s disease.
The epithelial cells that line the gut are smooth because the microvilli normally found on them have been blunted (green arrowhead). The area beneath the epithelial cells, the lamina propria, is filled with numerous round cells with a 'foamy' appearance: these are the macrophages (black arrowheads). Extracellular fat has also accumulated in this area (white arrowhead). The tissue is stained with hematoxylin and eosin stain.
IMAGE CREDIT: Micrograph by Nephron (CC BY-SA 3.0).
The bacterium was fastidious and could not be grown in the laboratory. In 1949, however, a new staining technique allowed the foamy cells, which are actually macrophages, to be recognized in affected tissues, thus enabling diagnosis of the disease (Black-Schaffer, 1949). Later, in 1961, electron microscopy identified the distinctive three layers of 'Whipple’s bacillus' (Yardley and Hendrix, 1961), and in 1992 genetic sequencing revealed it to be a previously unknown organism, which was designated Tropheryma whippelii and later renamed Tropheryma whipplei (Relman et al., 1992; La Scola et al., 2001). During this time it was also shown that antibiotics could transform Whipple’s disease into a treatable condition.
As with any disease, doctors seek to better understand the condition in order to improve diagnosis and treatment. PCR-based methods demonstrated that the organism was ubiquitous; for example, it was found in sewage water, human saliva and feces from people unaffected by Whipple’s disease (Maiwald et al., 1998; Street et al., 1999). Blood tests also revealed that human exposure was common (Raoult et al., 2000). So, why was the incidence of disease so low? Since T. whipplei could not be cultured conventionally, researchers could not develop experimental infection models to understand how the disease develops and what makes hosts susceptible. Thus, most researchers studied naturally occurring infections in humans, and made observations that were consistent with Whipple’s original description, including dysfunctional macrophages in affected patients.
Meanwhile, astute clinical observation opened an alternate line of investigations. In 1955, a familial case of Whipple’s disease was reported, involving a mother and only two of her five adult children. This implied a hereditary component of susceptibility (Puite and Tesluk, 1955), and while no further genetic studies were reported from that family, several similar cases were described in other families (Gross et al., 1959). These discoveries implied that genetic approaches could circumvent the microbe’s fastidiousness and finally provide insight into this obscure disease.
Guérin et al. – who are based in institutions in France, Qatar, the United States, and Australia – evaluated 26 members of a French family: four people had Whipple’s disease; five were carriers of the bacterium but did not have the disease; 13 were healthy non-carriers; and four were healthy individuals whose carrier status was unknown. Elegant genomic studies and bioinformatics analyses identified a new variant of IRF4 (the gene for an immune transcription factor) in all those with the disease; in all the carriers; in two of the healthy non-carriers; and in one whose carrier status was unknown. The new variant was very rare and did not appear in any genomics database. Each individual carried one copy of the rare variant alongside a more typical version of the gene (i.e. they were all heterozygous).
Molecular investigations revealed that the rare variant differed by one amino acid (a tryptophan in place of an arginine). This change compromised the protein’s ability to bind to DNA and activate transcription. However, the mutant version of the protein did not interfere with the normal version, meaning it did not exert a negative dominance effect. Instead, Guérin et al. presumed the susceptibility occurs because people must need working protein from both versions of this gene to be protected against the bacteria. This phenomenon is referred to as haploinsufficiency.
In experiments that capitalized on the unique expertise of Didier Raoult's lab in culturing T. whipplei in vitro, the loss-of-function in IRF4 was linked to a distinct gene expression profile in response to the bacterium. Similar results were seen for a related bacterium, Mycobacterium bovis strain BCG. The genes that were expressed differently in response to T. whipplei could not be organized into a defined pathway, but those that differed in the response to BCG highlighted the role of IRF4 in regulating macrophages in cell-mediated immunity.
Together these findings raise a number of exciting questions. First, which IRF4-expressing cell types mitigate the disease? What molecular pathway connects IRF4 to the recognition and effective control or eradication of T. whipplei? What is the basis for the macrophages and lipid accumulation phenotypes that characterize this disease? And are mutations in IRF4 or other molecules at play in other patients with Whipple’s disease? These and other questions can now be pursued, guided by the study of this single yet informative family. On a grander scale, this work also reinforces the value of studying humans, including those with rare inborn errors of immunity, to understand human immunobiology, using approaches that cross disciplines.
References
-
The tinctoral demonstration of a glycoprotein in Whipple's diseaseExperimental Biology and Medicine 72:225–227.https://doi.org/10.3181/00379727-72-17388
-
Whipple's disease; report of four cases, including two in brothers, with observations on pathologic physiology, diagnosis, and treatmentGastroenterology 36:65–93.
-
Description of Tropheryma whipplei gen. nov., sp. nov., the Whipple's disease bacillusInternational Journal of Systematic and Evolutionary Microbiology 51:1471–1479.https://doi.org/10.1099/00207713-51-4-1471
-
Environmental occurrence of the Whipple's disease bacterium (Tropheryma whippelii)Applied and Environmental Microbiology 64:760–762.
-
Whipple's diseaseThe American Journal of Medicine 19:383–400.https://doi.org/10.1016/0002-9343(55)90127-3
-
Cultivation of the bacillus of Whipple's diseaseNew England Journal of Medicine 342:620–625.https://doi.org/10.1056/NEJM200003023420903
-
Identification of the uncultured bacillus of Whipple's diseaseNew England Journal of Medicine 327:293–301.https://doi.org/10.1056/NEJM199207303270501
-
A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissuesBulletin of the Johns Hopkins Hospital 18:382–393.
-
Combined electron and light microscopy in Whipple's disease. Demonstration of "bacillary bodies" in the intestineBulletin of the Johns Hopkins Hospital 109:80–98.
Article and author information
Author details
Publication history
- Version of Record published: April 18, 2018 (version 1)
Copyright
© 2018, Vinh
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,043
- views
-
- 62
- downloads
-
- 1
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Immunodeficiency: Back from the brink of obscurity
eLife 7:e36649.
https://doi.org/10.7554/eLife.36649
Further reading
-
- Immunology and Inflammation
We studied lysosomal Ca2+ in inflammasome. Lipopolysaccharide (LPS) + palmitic acid (PA) decreased lysosomal Ca2+ ([Ca2+]Lys) and increased [Ca2+]i through mitochondrial ROS, which was suppressed in Trpm2-KO macrophages. Inflammasome activation and metabolic inflammation in adipose tissue of high-fat diet (HFD)-fed mice were ameliorated by Trpm2 KO. ER→lysosome Ca2+ refilling occurred after lysosomal Ca2+ release whose blockade attenuated LPS + PA-induced inflammasome. Subsequently, store-operated Ca2+entry (SOCE) was activated whose inhibition suppressed inflammasome. SOCE was coupled with K+ efflux whose inhibition reduced ER Ca2+ content ([Ca2+]ER) and impaired [Ca2+]Lys recovery. LPS + PA activated KCa3.1 channel, a Ca2+-activated K+ channel. Inhibitors of KCa3.1 channel or Kcnn4 KO reduced [Ca2+]ER, attenuated increase of [Ca2+]i or inflammasome activation by LPS + PA, and ameliorated HFD-induced inflammasome or metabolic inflammation. Lysosomal Ca2+ release induced delayed JNK and ASC phosphorylation through CAMKII-ASK1. These results suggest a novel role of lysosomal Ca2+ release sustained by ER→lysosome Ca2+ refilling and K+ efflux through KCa3.1 channel in inflammasome activation and metabolic inflammation.
-
- Immunology and Inflammation
The autoimmune disease lupus erythematosus (lupus) is characterized by photosensitivity, where even ambient ultraviolet radiation (UVR) exposure can lead to development of inflammatory skin lesions. We have previously shown that Langerhans cells (LCs) limit keratinocyte apoptosis and photosensitivity via a disintegrin and metalloprotease 17 (ADAM17)-mediated release of epidermal growth factor receptor (EGFR) ligands and that LC ADAM17 sheddase activity is reduced in lupus. Here, we sought to understand how the lupus skin environment contributes to LC ADAM17 dysfunction and, in the process, differentiate between effects on LC ADAM17 sheddase function, LC ADAM17 expression, and LC numbers. We show through transcriptomic analysis a shared IFN-rich environment in non-lesional skin across human lupus and three murine models: MRL/lpr, B6.Sle1yaa, and imiquimod (IMQ) mice. IFN-I inhibits LC ADAM17 sheddase activity in murine and human LCs, and IFNAR blockade in lupus model mice restores LC ADAM17 sheddase activity, all without consistent effects on LC ADAM17 protein expression or LC numbers. Anti-IFNAR-mediated LC ADAM17 sheddase function restoration is associated with reduced photosensitive responses that are dependent on EGFR signaling and LC ADAM17. Reactive oxygen species (ROS) is a known mediator of ADAM17 activity; we show that UVR-induced LC ROS production is reduced in lupus model mice, restored by anti-IFNAR, and is cytoplasmic in origin. Our findings suggest that IFN-I promotes photosensitivity at least in part by inhibiting UVR-induced LC ADAM17 sheddase function and raise the possibility that anifrolumab ameliorates lupus skin disease in part by restoring this function. This work provides insight into IFN-I-mediated disease mechanisms, LC regulation, and a potential mechanism of action for anifrolumab in lupus.
